SC
ADVM

Shay Capital’s Adverum Biotechnologies ADVM Stock Holding History

Shay Capital’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23,395
Closed -$331K – 270
2024
Q1 		$331K Buy
+23,395
New +$356K 0.05% 236

Other funds holding ADVM

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Shay Capital's ADVM Position: Q2 2024 in Review

Shay Capital sold out of Adverum Biotechnologies (ADVM) in Q2 2024, closing a stake of 23,395 shares — an estimated $331K sold.

Shay Capital first reported a position in ADVM in Q1 2024 and held it in 1 quarter. The position peaked at $331K in Q1 2024. 68 funds tracked by Wall St. Rank hold ADVM as of Q2 2024.

  • Shay Capital reported no remaining Adverum Biotechnologies position as of Q2 2024 after selling out during the quarter.
  • Shay Capital sold 23,395 Adverum Biotechnologies shares in Q2 2024, an estimated $331K.
  • Shay Capital first reported a position in Adverum Biotechnologies in Q1 2024 and held it in 1 quarter.
  • Shay Capital's Adverum Biotechnologies position peaked at $331K in Q1 2024.
  • 68 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2024.

Based on Shay Capital's 13F filing for Q2 2024, filed 14 Aug 2024.